Evidence map›Paper›PMID 28438217›Full record

ArticleMicrobiome2017

A powerful microbiome-based association test and a microbial taxa discovery framework for comprehensive association mapping.

Hyunwook Koh, Martin J Blaser, Huilin Li

Abstract read
In one paragraph

Article in Microbiome, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. The Lung Allograft Microbiome Associates with Pepsin, Inflammation, and Primary Graft Dysfunction.American journal of respiratory and critical care medicine · 2022
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. CombiningFrontiers in microbiology · 2022
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Hyunwook KohDepartment of Population Health and Environmental Medicine, New York University School of Medicine, New York, NY, 10016, USA.
Martin J BlaserDepartment of Medicine and Microbiology, New York University Langone Medical Center, New York, NY, 10010, USA.
Huilin LiDepartment of Population Health and Environmental Medicine, New York University School of Medicine, New York, NY, 10016, USA. huilin.li@nyumc.org.ORCID 0000-0002-8288-7068

Funding

Vaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ADRIANA HEGUY · 1985 to 2026
$83.1M
Disappearing gastrointestinal microbiota in epidemic obesity.R01DK090989 · NIDDK · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI BLASER, MARTIN J · 2010 to 2015
$7.4M
Oral microbiome in esophageal adenocarcinomaU01CA182370 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI AHN, JIYOUNG, PEI, ZHIHENG · 2014 to 2018
$2.7M
Novel Statistical Methods in Analyzing Microbiome Data for Longitudinal StudyR01DK110014 · NIDDK · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI LI, HUILIN · 2016 to 2019
$1.5M
NCI NIH HHS P30 CA016087NCI NIH HHS U01 CA182370NIDDK NIH HHS R01 DK090989NIDDK NIH HHS R01 DK110014
6 · The paper itself

Abstract

backgroundThe role of the microbiota in human health and disease has been increasingly studied, gathering momentum through the use of high-throughput technologies. Further identification of the roles of specific microbes is necessary to better understand the mechanisms involved in diseases related to microbiome perturbations.

methodsHere, we introduce a new microbiome-based group association testing method, optimal microbiome-based association test (OMiAT). OMiAT is a data-driven testing method which takes an optimal test throughout different tests from the sum of powered score tests (SPU) and microbiome regression-based kernel association test (MiRKAT). We illustrate that OMiAT efficiently discovers significant association signals arising from varying microbial abundances and different relative contributions from microbial abundance and phylogenetic information. We also propose a way to apply it to fine-mapping of diverse upper-level taxa at different taxonomic ranks (e.g., phylum, class, order, family, and genus), as well as the entire microbial community, within a newly introduced microbial taxa discovery framework, microbiome comprehensive association mapping (MiCAM).

resultsOur extensive simulations demonstrate that OMiAT is highly robust and powerful compared with other existing methods, while correctly controlling type I error rates. Our real data analyses also confirm that MiCAM is especially efficient for the assessment of upper-level taxa by integrating OMiAT as a group analytic method.

conclusionsOMiAT is attractive in practice due to the high complexity of microbiome data and the unknown true nature of the state. MiCAM also provides a hierarchical association map for numerous microbial taxa and can also be used as a guideline for further investigation on the roles of discovered taxa in human health and disease.

Indexed as

MetagenomeAlgorithmsBacteriaComputational BiologyHumansMicrobial ConsortiaMicrobial InteractionsMicrobial ViabilityMicrobiotaPhylogenyRegression AnalysisRNA, Ribosomal, 16SRNA, Ribosomal, 16SComprehensive association mappingMicrobial association testMicrobial group analysisPhylogenetic treeTaxonomic structureUpper-level taxa

Identifiers

PMID28438217
PMCPMC5402681

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.